Education
About Us
Working with TipRanks
Follow Us
Inventiva SA (GB:0RNK)
LSE:0RNK
0RNK Stock Chart & Stats
€5.61
€0.03(1.17%)
At close: 4:00 PM EST
€5.61
€0.03(1.17%)
Day’s Range― - ―
52-Week Range€2.29 - €6.19
Previous CloseN/A
Volume2.44K
Average Volume (3M)16.48K
Market Cap
€1.18B
Enterprise Value€730.49M
Total Cash (Recent Filing)€122.08M
Total Debt (Recent Filing)€57.13M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Mar 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding206,407,470
10 Day Avg. Volume29,766
30 Day Avg. Volume16,477
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.22
Price to Sales (P/S)8.85
P/FCF Ratio-1.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.75Price Target Upside55.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Funding RunwayProceeds from a recent US public offering have created a sizeable cash position that extends the operating runway into early 2027, reducing near‑term financing risk and supporting continued pivotal trial operations.
Clinical Trial Enrollment And ReadoutFull enrollment of the Phase 3 NATIV3 trial with planned topline data presentation at a major hepatology conference increases the probability of a definitive clinical readout that could significantly influence valuation.
Trial Design And EndpointsA randomized dosing structure, biopsy‑confirmed endpoints read by a central panel, and a composite primary endpoint of disease resolution or fibrosis improvement strengthen the trial's ability to generate robust data for regulatory consideration.
Bears Say
Concomitant Medication ConfoundingUse of GLP‑1 agonists and other diabetes therapies by a subset of participants could obscure the investigational treatment's effect and complicate interpretation of efficacy despite stratification measures.
Inventiva News
0RNK FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest share price was €2.29 and its highest was €6.19 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €1.18B.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Mar 30, 2026 which is in 33 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Sep 29, 2025. The company reported -€1.379 earnings per share for the quarter, missing the consensus estimate of -€0.546 by -€0.833.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Inventiva SA dividends here
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.24.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 206,407,470 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€1.379 in its last earnings report, missing expectations of -€0.546. Following the earnings report the stock price went up 1.167%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in GB:0RNK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
0RNK Stock 12 Month Forecast
Average Price Target
€8.75
▲(55.97% Upside)
Technical Analysis
Options Prices
Currently, No data available
---